Inflammation News and Research

RSS

Bladder cancer is the fourth most common cancer in men and the eighth most common in women

Bladder cancer is the fourth most common cancer in men and the eighth most common in women, according to the National Cancer Institute (NCI). It is expected to be diagnosed in 38,000 men and 15,000 women in the United States in 2003. Treatment is most successful when the disease is caught early.

18 Apr 2004

GlaxoSmithKline files asthma treatment drug for approval in Japan

GlaxoSmithKline plc announced today that it has filed SeretideTM DiskusTM for approval to the Japanese Ministry of Health, Labour and Welfare (MHLW) for the treatment of asthma in adults and children.

16 Apr 2004

Amount of adiponectin hormone lessens chance of heart attacks

Men with high levels of a Adiponectin hormone secreted by fat cells have a lesser chance of heart attacks, according to a new study that could lead to new ways to prevent and treat heart disease.

13 Apr 2004

Vitamin C can reduce levels of C-reactive protein, a marker of inflammation and chronic disease

Vitamin C supplements can reduce levels of C-reactive protein, a marker of inflammation and chronic disease risk in humans, according to a new study led by researchers at the University of California, Berkeley.

12 Apr 2004

Scientists studying vaccinia virus, a relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation

Scientists at the University of Illinois at Urbana-Champaign studying vaccinia virus, a close relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation, a crucial anti-viral immune response of host cells.

6 Apr 2004

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)

In a study of Han Chinese patients, researchers have for the first time directly linked a gene of the immune system to a severe adverse drug reaction called Stevens-Johnson syndrome (SJS), according to a Duke University Medical Center medical geneticist and collaborators in Taiwan.

1 Apr 2004

T-cells in lupus patients avoid apoptosis and are stimulated to produce antibodies against the patients own DNA

Researchers studying autoimmune diseases have found a molecular mechanism that explains how T-cells in lupus patients avoid apoptosis and are stimulated to produce antibodies against the patients own DNA.

1 Apr 2004

Heart disease can be reduced substantially by regularly treating existing gum infections

Reinforcing the relationship between periodontal disease and heart disease, oral biologists from the University at Buffalo have shown that levels of two inflammatory proteins known to raise the risk of heart disease can be reduced substantially by regularly treating existing gum infections.

31 Mar 2004

Launch of thin needle syringe for multiple sclerosis treatment

A study conducted in Denmark showed that 86% of Rebif®-treated patients found that injections were easier and less painful using the new needle. The pre-filled syringe of Rebif® with the new needle is available in the same dosages as the previous version and will continue to carry the same indication. It is currently being launched in Europe and will be available worldwide by the end of 2004.

31 Mar 2004

Newly diagnosed non-Hodgkin’s lymphoma linked to monkey virus DNA

Examination of tumors in patients with newly diagnosed non-Hodgkin’s lymphoma found that half of them show evidence of a monkey virus DNA that may have originated from contaminated polio vaccines.

30 Mar 2004

World’s largest biotechnology company acquires Tularik

Amgen Inc., the world’s largest biotechnology company, and Tularik Inc., a pioneer in drug discovery related to cell signaling and the control of gene expression, today jointly announced that they have signed a definitive merger agreement whereby Tularik will become a wholly-owned subsidiary of Amgen in a stock for stock transaction.

30 Mar 2004

Immunomodulator induces long-term anti-tumor activity

EntreMed, Inc., a clinical-stage biopharmaceutical company developing therapeutic candidates primarily for the treatment of cancer, today reported that three months following administration with ENMD 0996, preclinical animal models showed inhibition of metastases. Data presented demonstrated that ENMD 0996 specifically blocks the activity of basic fibroblast growth factor (FGF-2), a naturally-occurring protein that stimulates angiogenesis, but had no effect on other angiogenesis stimulators.

29 Mar 2004

A common antibiotic used to treat arthritis and acne shows promise for limiting the severity of spinal cord and brain injuries

When a fall, car crash, bullet, or knife crushes or cuts a spinal cord, the injury does not stop there. Rather, tissues continue to discharge toxic chemicals for hours, even days and weeks. These chemicals kill and disable nerve cells some distance away from the core injury, compounding the damage and making rehabilitation more difficult or impossible.

26 Mar 2004

Asthma study turns up new information on viral infections

Researchers know that viral infections can exacerbate asthma and, in turn, make people with the condition more sensitive to environmental exposures such as endotoxin. But how viral infections contribute to this sensitivity in airway cells has not been clear. A recent study led by investigators from the University of Iowa Roy J. and Lucille A. Carver College of Medicine and the Veterans Affairs Medical Center (VAMC) in Iowa City shows, for the first time, that viral infections may increase environmental sensitivity in lung epithelial (surface) cells by changing expression of receptors on those cells.

25 Mar 2004

Carbon Dioxide may be used in medical implants

Carbon dioxide, an environmentally friendly solvent for dyeing and dry cleaning, may become a valuable new tool for making medical implants, according to a study at Ohio State University.

23 Mar 2004

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Pfizer Inc and UCB Pharma today announced the approval of a new chewable formulation of Zyrtec® (cetirizine HCl) for the treatment of seasonal and perennial allergic rhinitis (inflammation of the nasal passages) and chronic idiopathic urticaria (itching and hives of unknown causes) in children aged two years and older. The approval by the US Food and Drug Administration makes Zyrtec the first and only prescription antihistamine available in both syrup and chewable form.

22 Mar 2004

Forward step in treatment of Allergic Rhinitis

Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company’s lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.

22 Mar 2004

Lupus Discovery May Lead To Improved Drugs

In an important development in the treatment of lupus as well as certain cancers, scientists at the Feinberg School of Medicine at Northwestern University have discovered how autoimmune lupus T cells stave off programmed cell death and drive production of autoantibodies directed against the body’s own DNA.

22 Mar 2004

Bacteria Live in the Esophagus!

The esophagus isn't merely a tube for food traveling from the mouth to the stomach, it also provides an environment for bacteria to live, according to a new study by NYU School of Medicine scientists that overturns the general belief that the esophagus is free of bacteria.

22 Mar 2004

New Theory About Alzheimer's Disease

A group of scientists at The Scripps Research Institute has proposed a new theory about the cause of Alzheimer's disease, the progressive neurodegenerative disorder that currently afflicts some 4.5 million Americans. According to the hypothesis, the disease arises as a consequence of inflammation, which creates abnormal metabolites out of normal brain molecules.

22 Mar 2004

Inflammation News and Research

Bladder cancer is the fourth most common cancer in men and the eighth most common in women

GlaxoSmithKline files asthma treatment drug for approval in Japan

Amount of adiponectin hormone lessens chance of heart attacks

Vitamin C can reduce levels of C-reactive protein, a marker of inflammation and chronic disease

Scientists studying vaccinia virus, a relative of smallpox, have determined that a gene necessary for virus replication also has a key role in turning off inflammation

Gene of immune system linked to severe adverse drug reaction called Stevens-Johnson syndrome (SJS)

T-cells in lupus patients avoid apoptosis and are stimulated to produce antibodies against the patients own DNA

Heart disease can be reduced substantially by regularly treating existing gum infections

Launch of thin needle syringe for multiple sclerosis treatment

Newly diagnosed non-Hodgkin’s lymphoma linked to monkey virus DNA

World’s largest biotechnology company acquires Tularik

Immunomodulator induces long-term anti-tumor activity

A common antibiotic used to treat arthritis and acne shows promise for limiting the severity of spinal cord and brain injuries

Asthma study turns up new information on viral infections

Carbon Dioxide may be used in medical implants

FDA approves new chewable formulation of Zyrtec® aimed at young allergy sufferers

Forward step in treatment of Allergic Rhinitis

Lupus Discovery May Lead To Improved Drugs

Bacteria Live in the Esophagus!

New Theory About Alzheimer's Disease

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News